Clinical outcome of patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) treated with pembrolizumab.

被引：3
|
作者：
Sinicrope, Frank A. [1 ]
Chakrabarti, Sakti [1 ]
Eiring, Rachel [1 ]
Mitchelll, Jessica L. [1 ]
Finnes, Heidi D. [1 ]
Hubbard, Joleen Marie [1 ]
McWilliams, Robert R. [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e24127
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e24127
引用
收藏
页数：2
相关论文
共 50 条
  • [1] On pembrolizumab (Keytruda) in microsatellite instability-high/mismatch repair deficient (MSI-h/MMRd) metastatic colorectal cancer (mCRC)
    Bekaii-Saab, Tanios S.
    ONCOLOGY-NEW YORK, 2021, 35 (07): : 380 - 380
  • [2] Clinicopathological features of microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) in Japanese patients.
    Kawazoe, Akihito
    Shitara, Kohei
    Noguchi, Masaaki
    Fukuoka, Shota
    Kuboki, Yasutoshi
    Bando, Hideaki
    Okamoto, Wataru
    Kojima, Takashi
    Doi, Toshihiko
    Ohtsu, Atsushi
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [3] Clinical outcomes in patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) in the pre-immunotherapy era.
    Zwart, Koen
    van der Baan, Frederieke
    Dixon, Matthew
    Frantz, Bryan
    Punt, Cornelis J. A.
    Koopman, Miriam
    Vink, Geraldine R.
    Roodhart, Jeanine
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 65 - 65
  • [4] THE HUMANISTIC BURDEN OF MICROSATELLITE INSTABILITY-HIGH (MSI-H) COLORECTAL CANCER (CRC) AND METASTATIC CRC (MCRC) PATIENTS TREATED WITH SUBSEQUENT LINE THERAPY: A SYSTEMATIC REVIEW
    Kohn, C. G.
    Nguyen, E.
    Miller, J. D.
    Nwokeji, E.
    Laurie, M.
    Kamble
    Khan, T.
    Masood, A.
    Korytowsky, B.
    VALUE IN HEALTH, 2017, 20 (09) : A454 - A454
  • [5] Safety and antitumor activity of pembrolizumab in patients with advanced microsatellite instability-high (MSI-H) colorectal cancer: KEYNOTE-164
    Le, D.
    Kavan, P.
    Kim, T.
    Burge, M.
    Van Cutsem, E.
    Hara, H.
    Boland, P.
    Van Laethem, J.
    Geva, R.
    Taniguchi, H.
    Crocenzi, T.
    Sharma, M.
    Atreya, C.
    Diaz, L.
    Liang, L.
    Marinello, P.
    Dai, T.
    O'Neill, B.
    ANNALS OF ONCOLOGY, 2018, 29
  • [6] The clinical courses of solid tumors with microsatellite instability-high (MSI-H)
    Inagaki, Yuichiro
    Ohara, Fumiya
    Yokota, Hirofumi
    Takeuchi, Yuki
    Sawa, Hitomi
    Miyao, Kotaro
    Takashi, Seki
    Arima, Junko
    Yoneyama, Eiji
    Sawa, Masashi
    ANNALS OF ONCOLOGY, 2021, 32 : S344 - S344
  • [7] Neoadjuvant Immunotherapy Effectiveness in Patients With Microsatellite Instability-High (MSI-H) Gastric Cancer
    Chubenko, Viacheslav A.
    Navmatulya, Alexander Y.
    Gerk, Ivan A.
    Sarmatov, Artem A.
    V. Egorenkov, Vitaliy
    Shelekhova, Ksenia A.
    Zykov, Evgeny N.
    V. Chernobrivceva, Vera
    Volkov, Nikita M.
    Moiseyenko, Vladimir M.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (05)
  • [8] KEYNOTE-164: Pembrolizumab for patients with advanced microsatellite instability high (MSI-H) colorectal cancer.
    Le, Dung T.
    Kavan, Petr
    Kim, Tae Won
    Burge, Matthew E.
    Van Cutsem, Eric
    Hara, Hiroki
    Boland, Patrick McKay
    Van Laethem, Jean-Luc
    Geva, Ravit
    Taniguchi, Hiroya
    Crocenzi, Todd S.
    Sharma, Manish
    Atreya, Chloe Evelyn
    Diaz, Luis A.
    Liang, Li Wen
    Marinello, Patricia
    Dai, Tong
    O'Neil, Bert H.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA
    Barata, Pedro
    Agarwal, Neeraj
    Nussenzveig, Roberto
    Gerendash, Benjamin
    Jaeger, Ellen
    Hatton, Whitley
    Ledet, Elisa
    Lewis, Brian
    Layton, Jodi
    Babiker, Hani
    Bryce, Alan
    Garje, Rohan
    Stein, Cy
    Kiedrowski, Lesli
    Saylor, Philip
    Sartor, Oliver
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [10] Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).
    Andre, Thierry
    Shiu, Kai-Keen
    Kim, Tae Won
    Jensen, Benny Vittrup
    Jensen, Lars Henrik
    Punt, Cornelis J. A.
    Smith, Denis Michel
    Garcia-Carbonero, Rocio
    Alcaide, Julia
    Gibbs, Peter
    De la Fouchardiere, Christelle
    Rivera, Fernando
    Elez, Elena
    Bendell, Johanna C.
    Le, Dung T.
    Yoshino, Takayuki
    Zhong, Wen Yan
    Fogelman, David R.
    Marinello, Patricia
    Diaz, Luis A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345